enlivex therapeutics ltd., a clinical stage immunotherapy company, engages in developing allogeneic drugs for immune system rebalancing. its product candidate is allocetra, an immunotherapy candidate, which is in phase iib clinical trial in patients with severe sepsis; that is in investigator-initiated phase ii clinical trial for the treatment of covid-19 patients in severe and critical conditions; and which is in phase iia clinical trial for the prevention of graft versus host disease in allogeneic hematopoietic stem cell transplants (hsct) patients. the company is also developing allocetra for the prevention of complications associated with bone marrow transplantations and/or hsct, and acute multiple organ failure. it also intends to develop its cell-based therapy to be combined with treatments of solid tumors via immune checkpoint rebalancing to enhance the efficacy of various anti-cancer therapies, including chimeric antigen receptor t-cell therapy and therapies targeting t-cell re
Company profile
Ticker
ENLV
Exchange
Website
CEO
Dror Mevorach
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
BIO BLAST PHARMA LTD., Bioblast Pharma Ltd.
SEC CIK
ENLV stock data
Latest filings (excl ownership)
6-K
Report of Foreign Private Issuer
16 Apr 24
6-K
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
11 Apr 24
6-K
Report of Foreign Private Issuer
29 Mar 24
6-K
Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method
7 Feb 24
6-K
Report of Foreign Private Issuer
22 Jan 24
6-K
Report of Foreign Private Issuer
17 Jan 24
6-K
Enlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis
20 Dec 23
6-K
Condensed Consolidated Financial Statements
9 Nov 23
6-K
Report of Foreign Private Issuer
7 Nov 23
6-K
Report of Foreign Private Issuer
2 Nov 23
Latest ownership filings
SC 13G/A
Beneficial ownership report (amended)
14 Feb 20
SC 13G/A
Enlivex Therapeutics Ltd.
9 Sep 19
SC 13G
Enlivex Therapeutics Ltd.
27 Jun 19
SC 13G
Enlivex Therapeutics Ltd.
26 Jun 19
SC 13G
Enlivex Therapeutics Ltd.
26 Jun 19
SC 13G
Enlivex Therapeutics Ltd.
19 Jun 19
SC 13D
Enlivex Therapeutics Ltd.
31 May 19
SC 13G/A
Bioblast Pharma Ltd.
14 Feb 19
SC 13G/A
Bioblast Pharma Ltd.
14 Feb 19
SC 13G/A
Bioblast Pharma Ltd.
14 Feb 18
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q2 2023
1.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 20 |
Opened positions | 1 |
Closed positions | 1 |
Increased positions | 3 |
Reduced positions | 7 |
13F shares | Current |
---|---|
Total value | 610.62 mm |
Total shares | 302.49 k |
Total puts | 10.30 k |
Total calls | 65.50 k |
Total put/call ratio | 0.2 |
Largest owners | Shares | Value |
---|---|---|
Compagnie Lombard Odier SCmA | 65.00 k | $171.15 mm |
Renaissance Technologies | 56.69 k | $149.00 k |
MS Morgan Stanley | 43.85 k | $115.21 mm |
Citadel Advisors | 38.62 k | $101.56 mm |
UBS UBS Group AG - Registered Shares | 17.81 k | $46.79 mm |
Susquehanna International | 15.09 k | $39.69 mm |
Edmond De Rothschild Holding | 13.00 k | $34.19 mm |
Simplex Trading | 12.68 k | $33.00 k |
GS Goldman Sachs | 11.30 k | $29.68 mm |
Geode Capital Management | 10.42 k | $27.40 mm |
News
Tesla To $180? Here Are 10 Top Analyst Forecasts For Friday
12 Apr 24
HC Wainwright & Co. Maintains Buy on Enlivex Therapeutics, Lowers Price Target to $7
12 Apr 24
Nasdaq Jumps 250 Points; Crude Oil Down 1%
11 Apr 24
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
11 Apr 24
Dow Dips 100 Points; CarMax Earnings Miss Views
11 Apr 24
Press releases
Enlivex Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis
16 Apr 24
Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis
11 Apr 24
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
11 Apr 24
Enlivex Therapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
22 Mar 24
Enlivex Receives Regulatory Authorization From Israel's Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritis
26 Feb 24